Organoids in petri dish
© Gouti Lab /Diecke TP | Felix Petermann, Max Delbrück Center

Technology portfolio

Download overview 

Related news & events

scientific image

Left: Muscle fibers expressing dysferlin (purple) made from gene-edited muscle stem cells transplanted into a mouse that lacks dysferlin. Right: Muscle fibers from the recipient mouse that are diseased and lack dysferlin.

© Andreas Marg, AG Spuler, ECRC
Press Release No. 1

Developing a CRISPR therapy for muscular dystrophy

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular dystrophy with the help of gene-editing. Preclinical research led by the Spuler Lab published in ​“Nature Communications” now paves the way for first-in-human clinical trials. 
woman
Science

From research to application

The Max Delbrück Center proudly welcomes Dr. Nevine Shalaby as the new Head of the Innovation and Entrepreneurship Department. With a rich background in genetics and industry, she aims to drive research impact, foster spin-offs, and strengthen industry partnerships, aligned with the Strategy 2030. 
Wissenschaftliches Bild
© David Ausserhofer, Max Delbrück Center
Press Release No. 22

Sharpening the gene scissors together

The Max Delbrück Center, Berlin, and the biotech company AlgenScribe from Nice have agreed to cooperate to further develop their gene-editing tools. The aim is to utilize synergies, accelerate research, and ultimately develop cell therapies for genetically determined diseases. 
Bild aus dem Labor
© Glycotope GmbH
Science

Research collaboration to improve immunotherapies

The Berlin biotech Glycotope and the Max Delbrück Center have signed an agreement to explore the potential of combining Glycotope’s tumor-specific antibodies with CAR technology developed by the Max Delbrück Center. Their common goal: advancing immunotherapies against solid tumors.